Olorinab Eases Abdominal Pain Associated with Crohn’s Disease in Phase 2a Trial

Olorinab Eases Abdominal Pain Associated with Crohn’s Disease in Phase 2a Trial
Olorinab, an investigational compound being developed by Arena Pharmaceuticals, significantly reduced chronic abdominal pain in patients with Crohn’s disease, according to topline results from a Phase 2a clinical trial. The findings also revealed a positive safety profile. Olorinab (APD371) is an oral, highly selective agonist of the cannabinoid receptor 2 (CB2) being developed as a therapy for visceral pain associated with gastrointestinal diseases, including Crohn's. Prior preclinical studies in models of chronic pain, including inflammatory bowel disease (IBD),
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *